Reimbursement approvals
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Belluscura PLC
("Belluscura" or the "Company" or "Group")
Reimbursement approval from U.S. Centers for Medicare & Medicaid Services (CMS)
X-PLO2R™ portable oxygen concentrator now covered by two Medicare reimbursement codes
LONDON, U.K. AND PLANO, TX, U.S. (29 November 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the Medicare Administrative Contractor Palmetto GBA MolDx ("Palmetto") has issued a final local coverage determination for the X-PLO2R™ portable oxygen concentrator ("X-PLO2R"). Weighing only 3.25 lbs (1.5kg), the X-PLO2R is the world's first portable modular oxygen concentrator.
Medicare reimbursement covers approximately 50% of the oxygen concentrator market in the US. The Board believes the approval of the two reimbursement codes will have a positive impact on the Company and expects to update shareholders on the full year outcome for FY21 in early January 2022.
Robert Rauker, CEO of Belluscura plc, commented: "Receiving the two Medicare reimbursement codes should further expand access and the use and distribution of the X-PLO2R throughout the US. We believe many Medicare patients will ask their health care providers and durable medical equipment providers to issue them with the lightweight X-PLO2R."
For further information please contact:
Belluscura plc | www.belluscura.com |
Robert Rauker, Chief Executive Officer | via Walbrook PR |
Anthony Dyer, Chief Financial Officer | |
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin | |
Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 |
James Serjeant / Nicholas Chambers | |
Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or [email protected] |
Paul McManus / Sam Allen | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.